DNA Vaccine Treatment in Dogs Experimentally Infected with Trypanosoma cruzi

Table 3

Cardiovascular parameters based on echocardiography in dogs experimentally infected with T. cruzi and treated with the DNA vaccine containing genes encoding a trans-sialidase protein (pBCSP), an amastigote-specific glycoprotein (pBCSSP4), or both as a mixture.

Group	Left ventricular (LV) diastolic diameter (mm)	Left ventricular (LV) systolic diameter (mm)	Fractional shortening (FS) (%)	Left ventricular ejection fraction (LVEF) (%)	Posterior wall (mm)	Septum (mm)	Left atrium (LA) diameter/aorta root (AR) diameter ratio
Healthy
Inf/SS mock-treated
pBCSSP4
pBCSP
Mixture
pBK-CMV

Group descriptions are shown in Table 1. Inf = infected. All data are expressed as the means and standard deviations. Significant difference () between the treatment groups and the healthy dogs and/or with reference values [80].